{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:34:50Z","timestamp":1793313290054,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:00:00Z","timestamp":1792972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clim.2026.110786","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:12:59Z","timestamp":1792797179000},"page":"110786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel CD123xV\u03b42 bispecific T cell engager induces potent and tumor selective V\u03b39V\u03b42-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome"],"prefix":"10.1016","volume":"288","author":[{"given":"Jurjen M.","family":"Ruben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte M.","family":"Mousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"van de Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milon","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Graeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Iglesias-Guimarais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline M.","family":"van Helden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton E.P.","family":"Adang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob C.","family":"Roovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"van der Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110786_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.clim.2026.110786_bb0010","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clim.2026.110786_bb0015","doi-asserted-by":"crossref","DOI":"10.1111\/jebm.70065","article-title":"Burden of myelodysplastic syndromes: a literature review of epidemiological and humanistic aspects","volume":"18","author":"Xie","year":"2025","journal-title":"J. Evid. Based Med."},{"key":"10.1016\/j.clim.2026.110786_bb0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0025","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2026.110786_bb0030","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/joim.13535","article-title":"Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia","volume":"292","author":"Woll","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0035","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2026.110786_bb0040","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.clim.2026.110786_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.clim.2026.110786_bb0055","article-title":"A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clim.2026.110786_bb0060","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark. Res."},{"key":"10.1016\/j.clim.2026.110786_bb0070","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood.V88.9.3391.bloodjournal8893391","article-title":"Expression of growth factor receptors in Unilineage differentiation culture of purified hematopoietic progenitors","volume":"88","author":"Testa","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cyto.b.20419","article-title":"Basophil activation test by flow cytometry: present and future applications in allergology","volume":"74","author":"Ebo","year":"2008","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.clim.2026.110786_bb0080","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0198-8859(02)00752-8","article-title":"Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions","volume":"63","author":"Dzionek","year":"2002","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.clim.2026.110786_bb0085","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.clim.2026.110786_bb0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/PAI.0b013e318261a342","article-title":"CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations","volume":"21","author":"Rollins-Raval","year":"2013","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.clim.2026.110786_bb0095","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12113087","article-title":"CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies","volume":"12","author":"El Achi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clim.2026.110786_bb0105","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/bloodadvances.2016002931","article-title":"High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression","volume":"1","author":"Wittwer","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2026.110786_bb0110","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41591-018-0333-y","article-title":"Publisher correction: myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level","volume":"25","author":"Chen","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.V122.21.359.359","article-title":"Leukemia stem cell marker CD123 (IL-3R alpha) predicts minimal residual disease and relapse, providing a valid target for SL-101 in acute myeloid leukemia with FLT3-ITD mutations","volume":"122","author":"Han","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0120","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","article-title":"Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm","volume":"4","author":"Pemmaraju","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2026.110786_bb0125","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/10428194.2017.1375107","article-title":"Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse","volume":"59","author":"Cummins","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.clim.2026.110786_bb0130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","article-title":"Bispecific antibodies for the treatment of acute myeloid leukemia","volume":"13","author":"Guy","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.clim.2026.110786_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032718","article-title":"CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm","volume":"24","author":"Pelosi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2026.110786_bb0140","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/2326-6066.CIR-23-0692","article-title":"The CD33xCD123xCD70 multispecific CD3-engaging DARPin MP0533 induces selective T cell-mediated killing of AML leukemic stem cells","volume":"12","author":"Bianchi","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.clim.2026.110786_bb0145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.clim.2026.110786_bb0150","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/bloodadvances.2023011858","article-title":"Dual-targeting CD33\/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile","volume":"8","author":"Zeng","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2026.110786_bb0155","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: Blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2026.110786_bb0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0165","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0175","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0180","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2026.110786_bb0185","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2026.110786_bb0190","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL V\u03b39V\u03b42-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"132","author":"De Weerdt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0195","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","article-title":"Human V\u03b39V\u03b42 T cells specifically recognize and kill acute myeloid leukemic blasts","volume":"188","author":"Gertner-Dardenne","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2026.110786_bb0200","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01401","article-title":"Current advances in \u03b3\u03b4 T cell-based tumor immunotherapy","volume":"8","author":"Lo Presti","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110786_bb0210","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.immuni.2020.02.014","article-title":"Butyrophilin-2A1 directly binds germline-encoded regions of the V\u03b39V\u03b42 TCR and is essential for Phosphoantigen sensing","volume":"52","author":"Karunakaran","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2026.110786_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.clim.2026.110786_bb0225","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4049\/jimmunol.176.3.1386","article-title":"Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation","volume":"176","author":"Devilder","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2026.110786_bb0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2026.110786_bb0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/science.1110267","article-title":"Professional antigen-presentation function by human gammadelta T cells","volume":"309","author":"Brandes","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.clim.2026.110786_bb0240","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0245","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284723","article-title":"Assessment of tumor-infiltrating TCRV \u03b3 9V \u03b4 2 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays","volume":"6","author":"Tosolini","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clim.2026.110786_bb0250","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/bloodadvances.2023011594","article-title":"Low frequency of V\u03b39V\u03b42 T cells predicts poor survival in newly diagnosed acute myeloid leukemia","volume":"8","author":"Le Floch","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2026.110786_bb0255","first-page":"23","article-title":"\u03b3\u03b4 T cell therapy for the treatment of non-small cell lung cancer","volume":"3","author":"Kakimi","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.clim.2026.110786_bb0260","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","article-title":"Phase I\/II study of adoptive transfer of \u03b3\u03b4 T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma","volume":"60","author":"Kobayashi","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2026.110786_bb0265","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"Gammadelta T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0270","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.clml.2023.02.003","article-title":"A phase I trial of allogeneic \u03b3\u03b4 T lymphocytes from Haploidentical donors in patients with refractory or relapsed acute myeloid leukemia","volume":"23","author":"Vydra","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clim.2026.110786_bb0275","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.jtct.2025.01.331","article-title":"Inb-100: pilot study of donor derived, ex-vivo expanded\/activated gamma-delta T cell infusion followinghaploidentical hematopoietic stem-cell transplantation and post-transplant cyclophosphamide","volume":"31","author":"McGuirk","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.clim.2026.110786_bb0280","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1200\/JCO.2025.43.16_suppl.6507","article-title":"\u03b39\u03b42 T-cell activation (\u03b3\u03b4TCA) with ICT01 combined with azacitidine-venetoclax (AV) for older\/unfit adults with newly diagnosed (ND) AML: preliminary efficacy and dose selection in phase 1\/2 study EVICTION","volume":"43","author":"Dumas","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2026.110786_bb0285","doi-asserted-by":"crossref","unstructured":"R.C.G. de Bruin, S.M. Lougheed, L. van der Kruk, A.G. Stam, E. Hooijberg, R.C. Roovers, P.M.P. van Bergen en Henegouwen, H.M.W. Verheul, T.D. de Gruijl, H.J. van der Vliet, Highly specific and potently activating V\u03b39V\u03b42-T cell specific nanobodies for diagnostic and therapeutic applications, Clin. Immunol. 169 (2016) 128\u2013138. doi:https:\/\/doi.org\/10.1016\/j.clim.2016.06.012.","DOI":"10.1016\/j.clim.2016.06.012"},{"key":"10.1016\/j.clim.2026.110786_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma Delta T-cell based Cancer immunotherapy: past-present-future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110786_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01062","article-title":"GMP-grade manufacturing of T cells engineered to express a defined \u03b3\u03b4TCR","volume":"9","author":"Straetemans","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110786_bb0300","first-page":"1054","article-title":"A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response","volume":"1","author":"Lameris","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.clim.2026.110786_bb0305","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-006-0180-4","article-title":"Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies","volume":"56","author":"Roovers","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2026.110786_bb0310","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1107\/S0907444908007877","article-title":"Structural characterization of a human Fc fragment engineered for lack of effector functions","volume":"64","author":"Oganesyan","year":"2008","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.clim.2026.110786_bb0315","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u201cKnobs-into-holes\u201d engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"10.1016\/j.clim.2026.110786_bb0320","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-23-0189","article-title":"A bispecific \u03b3\u03b4 T-cell engager targeting EGFR activates a potent V\u03b39V\u03b42 T cell-mediated immune response against EGFR-expressing tumors","volume":"11","author":"King","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.clim.2026.110786_bb0325","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20112655","article-title":"Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization","volume":"209","author":"McCoy","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0331-4","article-title":"Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment","volume":"10","author":"Nair-Gupta","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.clim.2026.110786_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111289","article-title":"Leveraging V\u03b39V\u03b42 T cells against prostate cancer through a VHH-based PSMA-V\u03b42 bispecific T cell engager","volume":"27","author":"King","year":"2024","journal-title":"IScience"},{"key":"10.1016\/j.clim.2026.110786_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/antib8010001","article-title":"Single-domain antibodies and their formatting to combat viral infections","volume":"8","author":"De Vlieger","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.clim.2026.110786_bb0345","article-title":"A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/icb.1996.1","article-title":"IL-3 receptor expression, regulation and function in cells of the vasculature","volume":"74","author":"Korpelainen","year":"1996","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.clim.2026.110786_bb0355","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110786_bb0360","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2022-168877","article-title":"Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy unicar-T-CD123 in relapsed\/refractory AML","volume":"140","author":"Ehninger","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0365","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0370","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1182\/blood-2023-190693","article-title":"A phase II study of Vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML","volume":"142","author":"Nguyen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0375","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110786_bb0380","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.2147\/OTT.S205678","article-title":"IFN-\u03b3 and TNF-\u03b1 aggravate endothelial damage caused by CD123-targeted CAR T cell","volume":"12","author":"Sun","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.clim.2026.110786_bb0385","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.clim.2026.110786_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246212","article-title":"The diverse roles of \u03b3\u03b4 T cells in cancer: from rapid immunity to aggressive lymphoma","volume":"13","author":"Sch\u00f6nefeldt","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clim.2026.110786_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01041","article-title":"Dual face of V\u03b39V\u03b42-T cells in tumor immunology: anti- versus pro-tumoral activities","volume":"8","author":"Xiang","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:26:32Z","timestamp":1793312792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":79,"alternative-id":["S1521661626001245"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110786","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel CD123xV\u03b42 bispecific T cell engager induces potent and tumor selective V\u03b39V\u03b42-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110786"}}